Palatin Technologies, Inc. Common Stock (PTN) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.417x

Based on the latest financial reports, Palatin Technologies, Inc. Common Stock (PTN) has a cash flow conversion efficiency ratio of -0.417x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.42 Million) by net assets ($10.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Palatin Technologies, Inc. Common Stock's balance sheet to measure how much of total assets are equity-financed.

Palatin Technologies, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (1996–2025)

This chart illustrates how Palatin Technologies, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check PTN cash flow quality score to evaluate the quality of earnings relative to operating cash generation.

Palatin Technologies, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Palatin Technologies, Inc. Common Stock ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Kingsmen C.M.T.I. Public Company Limited
BK:K
0.102x
Air Industries Group
NYSE MKT:AIRI
0.000x
Delorean Corporation Ltd
AU:DEL
-0.423x
Neuroone Medical Technologies Corp
NASDAQ:NMTC
-0.247x
Leyand International Tbk
JK:LAPD
0.140x
Genomtec S.A.
WAR:GMT
-0.262x
Botala Energy Ltd
AU:BTE
-0.032x
4Imprint Group Plc
LSE:FOUR
0.566x

Annual Cash Flow Conversion Efficiency for Palatin Technologies, Inc. Common Stock (1996–2025)

The table below shows the annual cash flow conversion efficiency of Palatin Technologies, Inc. Common Stock from 1996 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Palatin Technologies, Inc. Common Stock.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 $-4.78 Million $-21.31 Million 4.460x -98.42%
2024-06-30 $-111.50K $-31.46 Million 282.173x +1865.82%
2023-06-30 $-1.98 Million $-28.42 Million 14.354x +880.37%
2022-06-30 $16.27 Million $-29.92 Million -1.839x -303.25%
2021-06-30 $49.65 Million $-22.65 Million -0.456x -188.49%
2020-06-30 $80.17 Million $41.33 Million 0.515x +337.94%
2019-06-30 $100.55 Million $-21.78 Million -0.217x -443.00%
2018-06-30 $26.96 Million $1.70 Million 0.063x +102.53%
2017-06-30 $-5.16 Million $12.88 Million -2.494x -192.61%
2016-06-30 $-17.59 Million $-47.36 Million 2.693x +346.07%
2015-06-30 $12.20 Million $-13.36 Million -1.095x +12.23%
2014-06-30 $9.79 Million $-12.21 Million -1.247x -109.95%
2013-06-30 $22.98 Million $-13.65 Million -0.594x +92.98%
2012-06-30 $1.83 Million $-15.49 Million -8.459x -1295.05%
2011-06-30 $18.19 Million $-11.03 Million -0.606x +1.39%
2010-06-30 $9.32 Million $-5.73 Million -0.615x +62.57%
2009-06-30 $3.31 Million $-5.44 Million -1.643x +47.69%
2008-06-30 $6.55 Million $-20.58 Million -3.141x -163.94%
2007-06-30 $18.53 Million $-22.05 Million -1.190x +7.13%
2006-06-30 $18.30 Million $-23.45 Million -1.281x -133.44%
2005-06-30 $9.23 Million $-5.06 Million -0.549x +55.18%
2004-06-30 $19.39 Million $-23.74 Million -1.225x -14.86%
2003-06-30 $18.66 Million $-19.89 Million -1.066x +29.55%
2002-06-30 $8.69 Million $-13.15 Million -1.513x -114.75%
2001-06-30 $11.92 Million $-8.40 Million -0.705x +43.02%
2000-06-30 $6.91 Million $-8.54 Million -1.237x +96.43%
1999-06-30 $300.00K $-10.40 Million -34.667x -1492.79%
1998-06-30 $3.40 Million $-7.40 Million -2.176x -420.23%
1997-06-30 $9.80 Million $-4.10 Million -0.418x +56.18%
1996-06-30 $2.84 Million $-2.71 Million -0.955x --

About Palatin Technologies, Inc. Common Stock

NASDAQ:PTN USA Biotechnology
Market Cap
$14.64 Million
Market Cap Rank
#26031 Global
#5390 in USA
Share Price
$8.23
Change (1 day)
+6.88%
52-Week Range
$7.68 - $14.61
All Time High
$14.61
About

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, … Read more